SCHEMBL4304231

SCHEMBL4304231

COC(=O)c1cccc(NC(=O)Cc2ccccc2-c2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.59
HPGD P15428 1/20 0.59
RAB9A P51151 5/20 0.58
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
ANO1 Q5XXA6 1/20 0.54
MAPT P10636 2/20 0.54
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.53
MAPK1 P28482 2/20 0.53
PKM P14618 1/20 0.53
TSHR P16473 1/20 0.53
HSD17B10 Q99714 3/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
THRB P10828 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24799100 0.84 ANO1 (0.67) ALDH1A1HPGDRAB9ACYP1A2CYP3A4
SCHEMBL21198034 0.82 SMN1; SMN2 (0.71) ALDH1A1HPGDRAB9ACYP1A2CYP3A4
SCHEMBL28019937 0.82 KCNJ5 (0.67) ALDH1A1HPGDRAB9ACYP1A2CYP3A4
SCHEMBL31306535 0.82 SMN1; SMN2 (0.71) ALDH1A1HPGDRAB9ACYP1A2CYP3A4
SCHEMBL4298937 0.82 ALDH1A1 (0.65) ALDH1A1HPGDRAB9ACYP1A2CYP3A4
SCHEMBL8639463 0.81 CYP1A2 (0.63) ALDH1A1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL7170771 0.81 PTGER1 (0.54) RAB9ATSHRNPC1
SCHEMBL27397040 0.79 RAB9A (0.50) ALDH1A1HPGDRAB9AMAPTSMN1; SMN2
SCHEMBL9030520 0.76 L3MBTL1 (0.68) ALDH1A1HPGDRAB9ACYP1A2CYP3A4
SCHEMBL13576900 0.76 HIF1A (0.71) ALDH1A1HPGDRAB9ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394799-B2 Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2013-03-12 US disclosed
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT HIF1AN, HIF1A, VHL ALDH1A1 499/4885HPGD 867/4885RAB9A 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.